Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges

The poor solubility of paclitaxel (PTX), the most commonly used anticancer drug (Taxol ), has long hindered the development of successful formulations. In 2005, the launch of Abraxane , a human albumin-based preparation of PTX, competed with Taxol in the commercial market. The success of Abraxane pu...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2019-05, Vol.14 (10), p.1323-1341
Main Authors: Barkat, Md Abul, Beg, Sarwar, Pottoo, Faheem H, Ahmad, Farhan J
Format: Article
Language:English
Subjects:
Abraxane
Agriculture
Bioavailability
Breast cancer
Cancer therapies
chemotherapeutic agents
Collaboration
Drug delivery systems
Drug development
Drug dosages
Evolution
Metabolism
Metabolites
Metastasis
nano-formulation
Ovarian cancer
paclitaxel
Pharmaceutical industry
Response rates
Studies
Taxol
Trees
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The poor solubility of paclitaxel (PTX), the most commonly used anticancer drug (Taxol ), has long hindered the development of successful formulations. In 2005, the launch of Abraxane , a human albumin-based preparation of PTX, competed with Taxol in the commercial market. The success of Abraxane pushed other generic preparations aside, sparking competition among the global pharmaceutical companies to develop the novel and superior PTX nanotechnology-driven formulations. Unsurprisingly, the success underlying with cancer treatment using nano PTX therapy has now entered into a new era of drug development, patentability, preclinical and clinical evaluation, leading eventually to a significant increase in the regulatory approval of the products. The present article aims to provide recent progress in the development of nano PTX formulations by various pharmaceutical companies for safe and effective drug therapies for patients benefit.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2018-0313